v3.26.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2025
Dec. 31, 2024
Assets    
Cash and cash equivalents $ 14,438,792 $ 13,476,331
Prepaid clinical trial costs 0 540,601
Prepaid expenses and other current assets 664,685 666,435
Total current assets 15,103,477 14,683,367
Non-current prepaid clinical trial costs 819,721 819,721
Total Assets 15,923,198 15,503,088
Liabilities    
Short-term debt 406,875 458,154
Accounts payable 3,009,074 6,283,430
Accrued clinical expenses 2,582,094 6,723,719
Accrued compensation 485,899 635,587
Other accrued liabilities 791,611 500,616
Total current liabilities 7,275,553 14,601,506
Warrant liabilities 0 89,010
Total Liabilities 7,275,553 14,690,516
Commitments and Contingencies  
Stockholders’ Equity    
Common stock, par value of $0.0001; 515,000,000 and 315,000,000 shares authorized; 5,842,497 and 2,328,960 shares issued and outstanding as of December 31, 2025 and 2024, respectively 11,655 4,658
Preferred Stock, par value of $0.0001; 10,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2025 and 2024 0 0
Additional paid-in capital 192,773,942 165,080,964
Accumulated deficit (184,137,952) (164,273,050)
Total stockholders' equity 8,647,645 812,572
Total Liabilities and Stockholders’ Equity $ 15,923,198 $ 15,503,088